Know Cancer

or
forgot password

Ceftriaxone in Non-neutropenic Fever


N/A
N/A
22 Years
Open (Enrolling)
Both
Histiocytosis, Pediatric Patients With Cancer

Thank you

Trial Information

Ceftriaxone in Non-neutropenic Fever


Inclusion Criteria:



- Diagnosed with malignancy, Langerhans cell histiocytosis,or hemophagocytic
lymphohistiocytosis from 2007 through 2010

- Under 23 years at time of diagnosis of malignancy, Langerhans cell histiocytosis,or
hemophagocytic lymphohistiocytosis

- Treated at Monroe Carell Jr. Children's Hospital at Vanderbilt for aforementioned
diagnosis from 2007 through 2012

- While on immunosuppressive therapy with a central venous line in place had at least
one documented episode of fever (defined as ≥ 38.0°Celsius orally for over 30 minutes
or ≥ 38.3°Celsius orally x1).

Exclusion Criteria:

- Does not meet all inclusion criteria as stated above

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Retrospective

Outcome Measure:

Incidence of catheter-associated blood stream infections from all episodes of non-neutropenic fever in pediatric oncology, Langerhans cell histiocytosis or Hemophagocytic lymphohistiocytosis patients diagnosed and treated at Vanderbilt

Outcome Time Frame:

12 months

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

VICC PED1061

NCT ID:

NCT01225718

Start Date:

August 2010

Completion Date:

July 2013

Related Keywords:

  • Histiocytosis
  • Pediatric Patients With Cancer
  • Histiocytosis

Name

Location

Monroe Carrell Jr. Children's Hospital at VanderbiltNashville, Tennessee  37232